Literature DB >> 2420803

The analysis of lipopolysaccharide (endotoxin) in meningococcal polysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis.

C M Tsai.   

Abstract

A simple physical-chemical method for estimating the lipopolysaccharide (LPS, i.e. endotoxin) content of meningococcal polysaccharide vaccines is described. The low molecular weight LPS was first separated from the high molecular weight polysaccharide by SDS-polyacrylamide gel electrophoresis. The LPS was then selectively visualized by a highly sensitive silver stain which can detect 5 ng of meningococcal LPS. The method can detect concentrations of LPS in meningococcal polysaccharides as low as 0.01%, and was used to measure semiquantitatively the LPS in bulk powders of meningococcal polysaccharides and in vaccines in final containers. The LPS in the bulk powders and in the vaccines was also assayed by the gelation of Limulus polyphemus ameobocyte lysate and the results of the two methods were in agreement.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2420803     DOI: 10.1016/s0092-1157(86)80006-3

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  23 in total

1.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.

Authors:  A L Stone; S C Szu
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

3.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

4.  Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Authors:  F Oftung; L M Naess; L M Wetzler; G E Korsvold; A Aase; E A Høiby; R Dalseg; J Holst; T E Michaelsen; B Haneberg
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

5.  Multiple mechanisms in serum factor-induced resistance of Haemophilus influenzae type b to antibody.

Authors:  M Kuratana; E J Hansen; P Anderson
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

6.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  Neisserial porins inhibit human neutrophil actin polymerization, degranulation, opsonin receptor expression, and phagocytosis but prime the neutrophils to increase their oxidative burst.

Authors:  R Bjerknes; H K Guttormsen; C O Solberg; L M Wetzler
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.

Authors:  H K Guttormsen; L M Wetzler; A Naess
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  Quantitation and biological properties of released and cell-bound lipooligosaccharides from nontypeable Haemophilus influenzae.

Authors:  X X Gu; C M Tsai; M A Apicella; D J Lim
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.